STOCKS TELEGRAPH

Tag: NASDAQ:LTRN

  • After-Market Boost: Lantern Pharma (LTRN) Stock Jumps On Patent Progress

    After-Market Boost: Lantern Pharma (LTRN) Stock Jumps On Patent Progress

    Last Friday, Lantern Pharma Inc. (NASDAQ: LTRN) saw a noteworthy 6.00% after-hours stock rise, rising to $4.59. The company’s announcement of the publication of its Patent Cooperation Treaty (PCT) application, which covered an advanced machine learning method for predicting blood-brain barrier (BBB) permeability, was the catalyst for this upward momentum. A positive PCT search report was obtained for the application, emphasizing the lack of substantial prior art and increasing the likelihood that it would be approved.

    AI-Driven Innovation Is Strengthened by Patent Publication

    The unique method developed by Lantern Pharma has shown to be incredibly effective in forecasting BBB permeability for a wide variety of chemical substances. With its industry-leading precision and ability to handle up to 100,000 molecules per hour, the system is a milestone in computational drug development. Further demonstrating their technological prowess, the company’s AI algorithms presently occupy five of the top eleven spots on the Therapeutic Data Commons Leaderboard.

    It is anticipated that this predictive capacity would speed up drug discovery by finding substances that have a high probability of passing across the blood-brain barrier. This is especially important for the development of therapies that target brain tumors and illnesses of the central nervous system (CNS). By simplifying early-stage molecular characterisation, Lantern Pharma’s invention has the potential to drastically cut medication development time and expense.

    Industry Cooperation and Strategic Integration

    An important turning point in Lantern Pharma’s strategy efforts to transform drug development has been reached with the release of this AI-driven model. In addition to strengthening its own R&D skills, the business plans to work with technology-driven biotech and pharmaceutical companies to implement this high-performance BBB prediction engine. Through these collaborations, LTRN’s proficiency in predictive modeling for medication efficacy will be utilized to expedite therapeutic development timeframes.

    The system uses feature engineering based on chemical structure and bioactivity to combine synthetic data augmentation with sophisticated molecular representation techniques. This breakthrough greatly optimizes research and development efforts by enabling quick and thorough analysis of drug candidates when combined with Lantern’s proprietary RADR AI platform.

    Worldwide Patent Protection and Prospects

    With a possible 20-year coverage period from the date of filing, Lantern Pharma is well-positioned to obtain patent protection in significant international markets thanks to the PCT application. LTRN has started an expedited review procedure in the US to speed up commercialization.

  • After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals

    After-Hour Surge: Lantern Pharma (LTRN) Shares Climb On Regulatory Approvals

    Shares of Lantern Pharma Inc. (NASDAQ: LTRN) had a noteworthy boost on the last trading day of the week, jumping by 5.69% in after-hours trading to hit $3.99. This encouraging trend emerged after the stock finished the regular session with a minor 1.69% decrease, at $3.78. The stability of the stock can be ascribed to recent positive improvements in regulations.

    Regulatory Recognition and Designations

    Lantern Pharma’s investigational therapy candidate, LP-184, has been given three rare pediatric disease designations (RPDD) by the U.S. Food and Drug Administration. These designations are specific to hepatoblastoma, rhabdomyosarcoma (RMS), and malignant rhabdoid tumors (MRT).

    They show that the FDA recognizes the critical need for new medicines targeted at these challenging to treat conditions. Such acknowledgement demonstrates LTRN’s commitment to addressing the unique challenges in pediatric oncology.

    Innovative Approaches to Medicine Development

    Lantern Pharma is attempting to transform the landscape of cancer therapy development using data-driven strategies and artificial intelligence (AI). While drastically reducing research costs and timelines, the company hopes to increase patient accuracy with revolutionary medicines. The identification of three promising indications for LP-184 in pediatric cancers illustrates the company’s progress in this innovative endeavor.

    Implications of Rare Pediatric Disease Designation

    The RPDD designation confers various advantages, including the potential for a priority review voucher following the FDA’s approval of a product meeting certain conditions. These vouchers, often referred to as “golden tickets,” can expedite the review process for subsequent new drug applications (NDAs), decreasing the standard review time from ten months to six.

    Historically, these vouchers have been valued at approximately $100 million, providing significant opportunities for future development and commercialization. Lantern Pharma’s LP-184 is currently undergoing a multi-center Phase 1A clinical trial, anticipated to enroll approximately 50 to 60 patients.

    Depending on the trial outcomes and subsequent studies, the company plans to further develop clinical trials targeting specific pediatric populations afflicted by MRT, RMS, and hepatoblastoma. This strategic direction positions Lantern Pharma LTRN) as a key player in the fight against rare pediatric cancers.